These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

375 related items for PubMed ID: 16724367

  • 1. Biologic therapies for psoriasis. A systematic review.
    Boehncke WH, Prinz J, Gottlieb AB.
    J Rheumatol; 2006 Jul; 33(7):1447-51. PubMed ID: 16724367
    [Abstract] [Full Text] [Related]

  • 2. Advancements in the treatment of psoriasis: role of biologic agents.
    Rich SJ, Bello-Quintero CE.
    J Manag Care Pharm; 2004 Jul; 10(4):318-25. PubMed ID: 15298530
    [Abstract] [Full Text] [Related]

  • 3. Biologic therapy for psoriasis: an update on the tumor necrosis factor inhibitors infliximab, etanercept, and adalimumab, and the T-cell-targeted therapies efalizumab and alefacept.
    Weinberg JM, Bottino CJ, Lindholm J, Buchholz R.
    J Drugs Dermatol; 2005 Jul; 4(5):544-55. PubMed ID: 16167412
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Treatment of plaque psoriasis with biologics. A meta-analysis of randomized controlled trials].
    Zhang Z, Schmitt J, Wozel G, Kirch W.
    Med Klin (Munich); 2009 Feb 15; 104(2):125-36. PubMed ID: 19242664
    [Abstract] [Full Text] [Related]

  • 8. Economic evaluation of biologic therapies for the treatment of moderate to severe psoriasis in the United States.
    Anis AH, Bansback N, Sizto S, Gupta SR, Willian MK, Feldman SR.
    J Dermatolog Treat; 2011 Apr 15; 22(2):65-74. PubMed ID: 20443663
    [Abstract] [Full Text] [Related]

  • 9. An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis.
    Weinberg JM.
    Clin Ther; 2003 Oct 15; 25(10):2487-505. PubMed ID: 14667953
    [Abstract] [Full Text] [Related]

  • 10. Advances in therapy for psoriasis: an overview of infliximab, etanercept, efalizumab, alefacept, adalimumab, tazarotene, and pimecrolimus.
    Saini R, Tutrone WD, Weinberg JM.
    Curr Pharm Des; 2005 Oct 15; 11(2):273-80. PubMed ID: 15638763
    [Abstract] [Full Text] [Related]

  • 11. Biologic survival.
    Noiles K, Vender R.
    J Drugs Dermatol; 2009 Apr 15; 8(4):329-33. PubMed ID: 19363851
    [Abstract] [Full Text] [Related]

  • 12. Off-label uses of biologics in dermatology: rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (part 2 of 2).
    Graves JE, Nunley K, Heffernan MP.
    J Am Acad Dermatol; 2007 Jan 15; 56(1):e55-79. PubMed ID: 17190618
    [Abstract] [Full Text] [Related]

  • 13. Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials.
    Reich K, Burden AD, Eaton JN, Hawkins NS.
    Br J Dermatol; 2012 Jan 15; 166(1):179-88. PubMed ID: 21910698
    [Abstract] [Full Text] [Related]

  • 14. A review of biologic treatments for psoriasis with emphasis on infliximab.
    Pirzada S, Tomi Z, Gulliver W.
    Skin Therapy Lett; 2007 Apr 15; 12(3):1-4. PubMed ID: 17487347
    [Abstract] [Full Text] [Related]

  • 15. New biologic therapies for psoriatic disease.
    Bohjanen KA, Prawer SE.
    Minn Med; 2004 Mar 15; 87(3):34-6. PubMed ID: 15080292
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Biologicals in the treatment of psoriasis.
    Boker A, Kimball AB, Rolz-Cruz G.
    Curr Opin Investig Drugs; 2007 Nov 15; 8(11):939-46. PubMed ID: 17979028
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Cost effectiveness of biologic therapies for plaque psoriasis.
    Ahn CS, Gustafson CJ, Sandoval LF, Davis SA, Feldman SR.
    Am J Clin Dermatol; 2013 Aug 15; 14(4):315-26. PubMed ID: 23696234
    [Abstract] [Full Text] [Related]

  • 20. Biologic therapy in psoriasis: perspectives on associated risks and patient management.
    Papp KA, Dekoven J, Parsons L, Pirzada S, Robern M, Robertson L, Tan JK.
    J Cutan Med Surg; 2012 Aug 15; 16(3):153-68. PubMed ID: 22713438
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.